

1) The Manager-Listing

07.02.2017

National Stock Exchange of India Ltd Mumbai.

2) The Manager-Listing

BSE Ltd

Mumbai.

Dear Sir,

Sub: Out Come of the Board Meeting.

Ref: Regulation 33 of SEBI(LODR) Regulations, 2015.

As already informed to the exchanges, Board of Directors of the Company has met today and *inter alia* transacted the following business;

a) Approved the Un-audited stand alone and consolidated financial results of the Company for the quarter and nine months ended 31.12.2016.

A copy of the approved financial results along with Limited Review report issued by the statutory auditors of the Company is enclosed with this intimation.

Please take this intimation on record.

For Bal Pharma Limited

Shailesh Siroya Managing Director.







BAL PHARMA LIMITED

Regd.Office: 21-22 Bommasandra Industrial Area,Anekal Taluq,Bangalore 560 099
STANDALONE/CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2016
Phone:41239500,Fax:22354057,email:secretarial@balpharma.cor

CIN: L85110KA1987PLC008368

S. S.				STANE	STANDALONE					CONSOLIDATED	IDATED		
			Ouarter ended		Nine Months Ended	the Endad	Voar Endad		Ousrtor andad		Nina Monthe Endad	the Endad	Vone Endad
		31 Dec 16	30 Sep 16	31 Dec 15	31 Dec 16	31 Dec 15	31 Mar 16	31 Dec 16	30 Sep 16	31 Dec 15	31 Dec 16	31 Dec 15	31 Mar 16
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
PART I	T.1. 1 Income from Operations												
	a) Net Sales/Income from operations	5,729.41	6,414.60	4,765.57	16,545.96	14,495.77	19,832.90	5,750.13	6,487.60	4,790.07	16,743.92	14,535.87	19,898.91
	b) Other Operating Income	114.59	137.47	72.52	317.26	256.39	349.50	114.59	137.47	72.52	317.26	256.39	349.50
	Total Income from Operations	5,844.00	6,552.06	4,838.10	16,863.22	14,752.16	20,182.40	5,864.72	6,625.07	4,862.59	17,061.18	14,792.26	20,248.41
	2 Expenses												
	a) Consumption of Raw Materials/ Packing Materi	3,085.90	3,182.14	2,275.31	8,320.70	6,954.95	9,767.82	3,085.90	3,182.14	2,275.31	8,320.70	6,954.95	9,767.82
	b) Purchase of Stock in Trade	114.21	223.72	202.69	512.26	465.17	738.67	122.65	242.22	207.89	545.05	482.73	757.75
	c) Increase/decrease in stock in trade and WIP	-249.97	97.46	-313.34	-272.83	-33.58	-37.72	-280.00	81.19	-315.36	-326.30	-35.77	-47.48
	d) Employee Cost	1,042.11	1,071.96	873.34	3,059.33	2,608.35	3,567.19	1,161.25	1,184.89	916.13	3,377.28	2,694.63	3,734.55
-	e) Depreciation and amortisation expenses	131.75	140.43	161.36	421.50	473.04	697.42	132.64	141.38	162.24	424.07	475.54	700.90
	f) Other Expenditure	1,314.70	1,374.41	1,199.55	3,760.24	3,325.74	4,432.54	1,414.47	1,510.99	1,250.49	4,027.74	3,393.71	4,550.48
	g) Total	5,438.70	6,090.11	4,398.90	15,801.20	13,793.66	19,165.92	5,636.92	6,342.82	4,496.70	16,368.53	13,965.79	19,464.02
-	3 Profit from Operations before other Income, finance costs and Exceptional items(1-2) 405.3	e costs and 405.30	461.95	439.19	1,062.02	958.50	1,016.48	227.79	282.25	365.90	692.64	826.51	784.39
		2.											
	4 Other Income	2.67	137.54	13.76	217.57	107.22	149.61	2.67	137.54	10.78	217.57	104.24	128.33
	5 Profit before finance cost and Exceptional items (3-	407.97	599,50	452.95	1,279.58	1,065.72	1,166.09	230.46	419.79	376.68	910.21	930.75	912.72
	6 Finance Costs	202.23	219.32	170.99	615.12	438.44	647.66	202.65	219.47	171.03	615.74	438.51	647.77
	7 Profit after finance cost but before Exceptional iten	205.74	380.17	281.96	664.47	627.28	518.44	27.81	200.32	205.65	294.47	492.24	264.95
	8 Exceptional items	·	r		r	ï	ř	£		i	. *	,	,
	9 Profit/Loss from ordinary activities Before Tax (7-	205.74	380.17	281.96	664.47	627.28	518.44	27.81	200.32	205.65	294.47	492.24	264.95
	10 Tax expenses	53.68	113.73	80.49	186.80	169.33	237.83	52.97	113.20	90.22	185.58	169.33	239.01
	11 Net Profit /Loss from ordinary Activities after Tax	152.06	266.44	201.46	477.66	457.94	280.60	-25.16	87.11	115.42	108.89	322.90	25.94
	12 Extra ordinary items	ı	Υ	7	1	i		3	9	,	1	1	

1 Tana for the section	10001		27.000	***		1,000	111111111111111111111111111111111111111					
13 INST PROUT / LOSS FOR the Period	152.06	266.44	201.46	477.66	457.94	280.60	-25.16	87.11	115.42	108.89	322.90	25.94
14 Minority interest	e e	t		,	ī	1	-85.95	-87.91	-73.42	-177.49	-132.35	-114.60
15 Net Profit / Loss after taxes and minority interest	152.06	266.44	201.46	477.66	457.94	280.60	82.09	175.02	189.05	286.38	455.26	140.54
16 Paid-up Equity Share capital (face value of Rs 10 e	1,417.24	1,417.24	1,287.24	1,417.24	1,287.24	1,287.24	1,417.24	1,417.24	1,287.24	1,417.24	1,287.24	1,287.24
17 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year												
18 Earnings Per Share (of Rs 10 each) (Not annualised)												蒙
a) Basic	1.07	0.80	1.57	3.37	3.44	2.18	0.43	0.12	1.52	0.77	1.73	1.73
b) Diluted	1.07	0.80	1.57	3.37	3.44	2.18	0.43	0.12	1.52	0.77	1.73	1.73

A Particulars of Shareholding				W								
1) Public shareholding	78,86,570	78,86,570	65,86,570	78,86,570	65,86,570	65,86,570	78,86,570	78,86,570	65,86,570	78,86,570	65,86,570	65,86,570
- Number of Shares	55.65	55.65	51.17	55.65	51.17	51.17	55.65	55.65	51.17	55.65	51.17	51.17
- Percentage of shareholding												
2) Promoters & Promoter group Shareholding												
a) Pledged / Encumbered												
- Number of Shares												
- Percentage of shareholding												
b) Non-encumbered												
- Number of Shares	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802
- Percentage of shares (as a % of total shareholding	. 50											
of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
- Percentage of shareholding (as a % of total share												
capital of the company)	44.35	44.35	48.83	44.35	48.83	48.83	44.35	44.35	48.83	44.35	48 83	48.83

Received during the quarter

豆豆豆豆 Remaining unresolved at the end of the quarter Pending at the beginning of the quarter Disposed of during the quarter B Investor Complaints

Notes:

1 The above unaudited financial results as reviewed by the audit committee were approved by the Board of Directors at its meeting held on 07th February 2017.

2 Statutory auditors have conducted limited review on the unaudited financial results for the quarter ended 31.12.16

3 Previous year figures were regrouped/rearranged to conform to the classification of current year.

4 As the company deals with single product i. e pharmaceuticals, segment wise figures are not furnished.

For Bal Pharma limited Managing Director Shailesh Siroya

By order of the Board of Directors

07-02-2017 Bangalore



T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

CA T.D. JAIN B.Com., F.C.A.
CA DHANPAL I SAKARIA
B.Com., F.C.A.

34, Keshava Nivas, 3rd Floor First Main, Gandhinagar Bangalore-560 009 Phone: 22356135, 22356137

Telefax: 080-22356136

E-mail: ostawaljain@gmail.com

LIMITED REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIALS RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2016

To Board of Directors Bal Pharma Limited

We have reviewed the unaudited financial results of BAL PHARMA LIMITED ("the company") for the quarter and nine months ended 31 December, 2016 which are included in the accompanying statement of unaudited financial results for the quarter ended December 31 2016 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA Chartered Accountants Firm registration no: 002491S

AND DI

CHARTERED ACCOUNTANTS

T D JAIN
Partner

M No: 012034

Place: Bangalore Date: 06.02.2017



T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

CA T.D. JAIN B.Com., F.C.A.
CA DHANPAL I SAKARIA
B.Com., F.C.A.

34, Keshava Nivas, 3rd Floor First Main, Gandhinagar Bangalore-560 009

Phone: 22356135, 22356137 Telefax: 080-22356136

E-mail: ostawaljain@gmail.com

LIMITED REVIEW REPORT ON THE CONSOLIDATED UNAUDITED FINANCIALS RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2016

To Board of Directors Bal Pharma Limited

We have reviewed the consolidated unaudited financial results of BAL PHARMA LIMITED ("the company") and its subsidiaries (hereafter referred to as the "Group") for the quarter and Nine months ended 31 December 2016 which are included in the accompanying Unaudited Consolidated Financial results for the quarter ended December 31 2016 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the" "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

The statement includes the financial results of following entities:

Lifezen Healthcare Private Limited	Subsidiary
Balance Clinics LLP	Subsidiary
Bal Research Foundation	Subsidiary

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results, prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA Chartered Accountants Firm registration no: 002491S

T D JAIN Partner

M No: 012034

Place: Bangalore Date: 06.02.2017

